Metronidazole Fresenius (Metronidazole)

Metronidazole enters susceptible bacteria and protozoa and is reduced inside the cell to reactive nitro radicals. These radicals damage DNA and inhibit nucleic acid synthesis, leading to cell death. The reduction process occurs preferentially in anaerobic organisms, sparing most aerobic cells.

The dosage of Metronidazole Fresenius is determined by the prescribing clinician based on the infection type, severity, patient weight, renal and hepatic function, and other clinical factors. Only a qualified healthcare professional should set the exact dose and administration schedule.

Metronidazole is classified as Pregnancy Category B, indicating that animal studies have not shown risk but there are limited human data. It should be used only if the potential benefit justifies the potential risk. Small amounts are excreted in breast milk; breastfeeding decisions should be made with a healthcare provider.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and required import documentation.

Metronidazole is a nitroimidazole that specifically targets anaerobic bacteria and certain protozoa, offering rapid bactericidal activity. Compared with broad‑spectrum agents like clindamycin or beta‑lactams, metronidazole has a narrower spectrum focused on anaerobes, which can reduce collateral impact on normal flora but may require combination therapy for mixed infections.

Metronidazole Fresenius for injection should be stored at 2‑8 °C (refrigerated). Keep the vial in its original packaging, protect it from light, and do not freeze or shake the solution. Follow aseptic techniques when preparing the dose for intravenous administration.

The product is supplied as a sterile injection for intravenous use. It is administered by a qualified healthcare professional, typically as a slow infusion over a specified period. The exact rate and duration are determined by the prescriber based on the clinical situation and patient tolerance.

Serious adverse reactions include seizures, peripheral neuropathy, severe allergic responses such as anaphylaxis, Stevens‑Johnson syndrome, hepatotoxicity, and neutropenia. Patients should be monitored for neurological symptoms, skin reactions, and liver function abnormalities, especially during prolonged therapy.

Metronidazole should be avoided in patients with known hypersensitivity to the drug or other nitroimidazoles. Caution is advised for individuals with severe hepatic impairment, those taking disulfiram, or patients with a history of seizures or peripheral neuropathy. Pregnant or breastfeeding women should use it only when clearly indicated.